S. Mamede do Coronado, Portugal

Rita Gusmão De Noronha

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Bial-Portela & Cª, S.a.. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rita Gusmão De Noronha. Retrieved from https://idiyas.com/inventor/rita-gusmão-de-noronha

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rita Gusmão De Noronha: Innovator in Pharmaceutical Chemistry

Introduction

Rita Gusmão De Noronha is a notable inventor based in S. Mamede do Coronado, Portugal. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as inhibitors for specific enzymes.

Latest Patents

Rita holds a patent for "Imidazolecarboxamides and their use as FAAH inhibitors." This patent describes a compound that may be utilized as an inhibitor of fatty acid amide hydrolase, which plays a crucial role in various biological processes. The compound is characterized by a specific structure or a pharmaceutically acceptable salt thereof. She has 1 patent to her name.

Career Highlights

Throughout her career, Rita has worked with Bial-Portela & Cª, S.A., a prominent company in the pharmaceutical industry. Her work has contributed to advancements in drug development and therapeutic applications.

Collaborations

Rita has collaborated with notable professionals in her field, including Carla Patrícia Da Costa Pereira Rosa and Laszlo Erno Kiss. These collaborations have further enriched her research and innovation efforts.

Conclusion

Rita Gusmão De Noronha exemplifies the spirit of innovation in pharmaceutical chemistry. Her work on FAAH inhibitors showcases her commitment to advancing medical science and improving therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…